We have located links that may give you full text access.
Journal Article
Review
Future directions of antifungal chemotherapy.
Clinical Infectious Diseases 1992 March
The number of recognized fungal pathogens and the alternatives for treatment of infections due to these organisms have increased dramatically in the 1980s. Use of the traditional agent, amphotericin B, has been hampered by severe dose-limiting toxicity and variable efficacy, and flucytosine is characterized by a narrow spectrum, rapid emergence of resistance, and significant dose-limiting toxicities. In recent years, the appearance of a variety of azole antifungal drugs has permitted exploration of the use of different agents in a wide range of dosages for treatment of a variety of fungal infections. Even so, the azoles are often ineffective or cannot be used, and major therapeutic gaps still remain, particularly for patients with AIDS and those with severe neutropenia. For those with acute, life-threatening disease, the use of amphotericin B-lipid complex or ampholiposomes offers the potential of delivering much higher doses of amphotericin B safely. However, the efficacy of these formulations compared with that of amphotericin B is as yet uncertain. In addition to treatment of established disease, there has been interest in using antifungal azoles for prophylaxis for mucocutaneous candidiasis and systemic mycoses in patients who are predisposed to these conditions. Recently completed large-scale studies suggest that antifungal prophylaxis can be accomplished with use of azoles; however, the cost versus benefits of the prophylactic use of these agents is not yet defined. The 1990s will see consolidation of the uses of antifungals presently available, exploration of the use of much higher doses of amphotericin B (perhaps other polyenes as well in liposomal form), and perhaps the use of azoles in combination as well as alone or sequentially in the form of polyene/azole antifungal therapy. New entries may include beta-1,3-glucan inhibitors in the mid-1990s and other classes of drugs toward the end of the decade.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app